Biotech News
Related news
OTLKOutlook2026-04-22 12:30 EST
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
OTLKOutlook2026-04-23 20:05 EST
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
PRQRProQR Therapeutics2026-06-25 10:35 EST
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
MGTXMeiraGTx2026-04-16 11:48 EST
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
HROWHarrow, Inc.2026-03-24 20:57 EST
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
OCGNOcugen2026-05-04 20:01 EST
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
TARSTarsus Pharmaceuticals2026-08-06 11:02 EST
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
IRIXIRIDEX2026-07-20 11:00 EST
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
HROWHarrow, Inc.2026-03-24 12:15 EST
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
KPRXKiora Pharmaceuticals2026-04-07 11:00 EST
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
Outlook
Outlook Therapeutics is an ophthalmology company focused on retinal disease and anti-VEGF therapy delivery. Its story centers on whether it can create a differentiated eye-care franchise.
Recent company news
OTLKOutlook2026-08-06 12:45 EST
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
OTLKOutlook2026-07-24 18:40 EST
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
OTLKOutlook2026-06-16 12:02 EST
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
OTLKOutlook2026-06-01 12:46 EST
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
OTLKOutlook2026-05-28 20:00 EST
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Stock data
- Close
- 0.97 USD
- Market cap
- 120.89M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States